Pachychoroid Spectrum Diseases in Patients with Cushing's Syndrome: A Systematic Review with Meta-Analyses.
Cushing’s disease
central serous chorioretinopathy
meta-analysis
pachychoroid spectrum
polypoidal choroidal vasculopathy
systematic review
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
26
06
2022
revised:
11
07
2022
accepted:
28
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Cushing's syndrome is a rare disease with an endogenous cause of excess cortisol secretion. More evidence substantially links cortisol levels to the pachychoroid spectrum diseases. In this systematic review and meta-analysis, we summarize available evidence on pachychoroid spectrum diseases in patients with Cushing's syndrome. We performed a systematic literature search in 11 databases on 21 May 2022. Studies were considered eligible if they performed retinal examination of a consecutive group of patients with Cushing's syndrome using optical coherence tomography (OCT) scans. We extracted data on subfoveal choroidal thickness in patients with Cushing's syndrome compared to matched controls. We also extracted data on the prevalence of pachychoroid pigment epitheliopathy (PPE), central serous chorioretinopathy (CSC), and polypoidal choroidal vasculopathy (PCV). We identified six eligible studies with a total of 159 patients with Cushing's syndrome. On average, patients with Cushing's syndrome have 49.5 µm thicker subfoveal choroidal thickness compared to matched healthy individuals. Pachychoroid spectrum diseases were relatively common in these patients: PPE in 20.8%, CSC in 7.7%, and PCV in 2.8%. We conclude that there should be low threshold to recommend ophthalmic examination to patients with Cushing's syndrome, and that a macular OCT is recommended during this examination.
Identifiants
pubmed: 35956052
pii: jcm11154437
doi: 10.3390/jcm11154437
pmc: PMC9369356
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Prog Retin Eye Res. 2022 Mar;87:100994
pubmed: 34280556
Prog Retin Eye Res. 2022 Jan;86:100973
pubmed: 34029721
Retina. 2019 Feb;39(2):408-414
pubmed: 29266048
Ageing Res Rev. 2016 Aug;29:42-9
pubmed: 27262495
Eur J Endocrinol. 2015 Oct;173(4):M33-8
pubmed: 26156970
Acta Ophthalmol. 2021 Aug;99(5):470-477
pubmed: 33124181
Eur J Endocrinol. 2015 Apr;172(4):R143-9
pubmed: 25722097
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Acta Ophthalmol. 2022 May 28;:
pubmed: 35633142
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2583-2590
pubmed: 31219532
Acta Ophthalmol. 2021 Aug;99(5):533-537
pubmed: 33196148
Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1535-1542
pubmed: 35067771
Sci Rep. 2021 Feb 2;11(1):2748
pubmed: 33531597
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2377-2388
pubmed: 35486378
Ophthalmology. 2021 Jan;128(1):121-129
pubmed: 32619546
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
J Clin Endocrinol Metab. 2022 Jan 18;107(2):512-524
pubmed: 34546342
Retina. 2017 Mar;37(3):536-543
pubmed: 27429387
Acta Ophthalmol. 2016 Jun;94(4):386-90
pubmed: 26928876
Acta Ophthalmol. 2022 Feb 18;:
pubmed: 35179828
Acta Ophthalmol. 2021 Sep;99(6):e806-e822
pubmed: 33258304
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2075-85
pubmed: 25619667
Case Rep Ophthalmol Med. 2017;2017:9650287
pubmed: 29138701
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
J Evid Based Med. 2015 Feb;8(1):2-10
pubmed: 25594108
Front Endocrinol (Lausanne). 2016 Dec 09;7:154
pubmed: 28018289
Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101521
pubmed: 33766428
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120